Prof. Weiding Wu 吴伟顶
Chief Physician, Professor
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive surgery (robotic/laparoscopic) for pancreatic, liver, and biliary tumors. Focuses on function-preserving procedures for benign pancreatic tumors and multidisciplinary treatment for malignant pancreatic tumors.
Dr. Wu is Deputy Director of Pancreatic Surgery and the Minimally Invasive Surgery Center at Fudan University Shanghai Cancer Center, and Assistant Director of the Shanghai Pancreatic Tumor Institute. A visiting scholar at Cleveland Clinic in 2017, Dr. Wu performs over 500 complex pancreatic and biliary surgeries annually, with expertise in laparoscopic function-preserving procedures and extended radical pancreatectomy.
Professional roles
- Assistant Director, Shanghai Pancreatic Tumor Institute
- Vice Chair, Pancreatic Tumor Integrated Rehabilitation Committee, China Anti-Cancer Association
- National Committee Member, Digital Medical Surgery, Chinese Research Hospital Association
- Committee Member, Liver Cancer Study Group, Chinese Research Hospital Association
Name order: in Chinese the family name comes first (Wu Weiding). Papers usually list the name as Weiding Wu or Wu W.
Selected publications
19 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Gastroenterol, 2026 (senior author): Mucosal-associated invariant T cells promote PDAC progression via TL1A-CSF-1 axis. PubMed 42340414
- Front Immunol, 2026 (senior author): Overcoming multidimensional immunotherapy resistance in PDAC: from microenvironment to clinic. PubMed 41929491
- J Exp Clin Cancer Res, 2025 (senior author): Neurogenic inducers inhibit the proliferation of pancreatic cancer by promoting tumor cell transdifferentiation. PubMed 41225636
- Genomics, 2025 (senior author): Genomic mutation and Clinicopathological features of KRAS wild-type tumors in Chinese cohort with pancreatic adenocarcinoma. PubMed 40274200
- Comput Struct Biotechnol J, 2024 (senior author): The complement C3a/C3aR pathway is associated with treatment resistance to gemcitabine-based neoadjuvant therapy in pancreatic cancer. PubMed 39469671
- Cell Death Dis, 2023 (senior author): Knockdown of TACC3 inhibits tumor cell proliferation and increases chemosensitivity in pancreatic cancer. PubMed 38012214
- Biochim Biophys Acta Rev Cancer, 2023 (senior author): Focus on mast cells in the tumor microenvironment: Current knowledge and future directions. PubMed 36476563
- J Minim Access Surg, 2022 (senior author): Indocyanine green real-time-guided laparoscopic duodenum-preserving pancreatic head resection. PubMed 36124475
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion